Applegate K G, Balch C M, Pellis N R
Department of General Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Cancer Res. 1990 Nov 15;50(22):7153-8.
Antitumor immunity requires (a) extravasation of lymphocytes from the blood stream to interstitium, (b) locomotion through extracellular matrix to the site of the tumor, (c) effector cell recognition of the tumor target with cell/cell contact and binding of adhesion receptors, (d) T-cell receptor binding to histocompatibility and tumor antigens, and (e) tumor cell lysis. We hypothesize that the tumor microenvironment inhibits lymphocyte locomotion through extracellular matrix as one mechanism by which tumors may avert host defense. Lymphocyte locomotion was investigated in vitro using a three-dimensional collagen gel model. Fresh tumor-infiltrating lymphocytes (TIL) were obtained by enzymatic digestion of melanomas and renal cell carcinoma, and mononuclear cells were isolated by discontinuous Ficoll-Hypaque gradient. The lymphocytes were analyzed for motility from a point of origin between basal and overlay layers of collagen gel. Results showed that TIL migration was almost completely inhibited, compared with migration of normal and cancer patient peripheral blood leukocytes and lymphocytes from lymph nodes. Short-term (24-h) exposure of lymphocytes to cytokines during the assay in the collagen gel matrix had no effect on locomotor ability. Long-term (19, 30, or 35 days) culture of TIL in 200 units/ml of interleukin 2 reinstated locomotor ability. Short-term exposure of any of the lymphocyte populations to interleukin 1-alpha, interleukin 1-beta, interleukin 2, interleukin 3, interleukin 4, alpha-interferon, or gamma-interferon had no effect on migration. Thus, TIL display a uniquely arrested ability to locomote through collagen gel. Inhibition of the locomotion of infiltrating effector cells is possibly a mechanism by which the tumor evades the host immune system.
(a)淋巴细胞从血流外渗至间质;(b)通过细胞外基质移动至肿瘤部位;(c)效应细胞通过细胞/细胞接触识别肿瘤靶标并结合黏附受体;(d)T细胞受体与组织相容性和肿瘤抗原结合;以及(e)肿瘤细胞裂解。我们推测肿瘤微环境抑制淋巴细胞通过细胞外基质的移动,这可能是肿瘤逃避宿主防御的一种机制。使用三维胶原凝胶模型在体外研究淋巴细胞的移动。通过对黑色素瘤和肾细胞癌进行酶消化获得新鲜的肿瘤浸润淋巴细胞(TIL),并通过不连续的Ficoll-泛影葡胺梯度分离单核细胞。从胶原凝胶的基底层和覆盖层之间的起始点分析淋巴细胞的运动能力。结果显示,与正常人和癌症患者外周血白细胞以及淋巴结淋巴细胞的迁移相比,TIL的迁移几乎完全受到抑制。在胶原凝胶基质中检测期间,淋巴细胞短期(24小时)暴露于细胞因子对其运动能力没有影响。TIL在200单位/毫升白细胞介素2中进行长期(19、30或35天)培养可恢复其运动能力。任何淋巴细胞群体短期暴露于白细胞介素1-α、白细胞介素1-β、白细胞介素2、白细胞介素3、白细胞介素4、α-干扰素或γ-干扰素对迁移均无影响。因此,TIL在通过胶原凝胶移动方面表现出独特的停滞能力。浸润性效应细胞移动的抑制可能是肿瘤逃避宿主免疫系统的一种机制。